The purpose of this research study to determine if treating recurrent malignant gliomas with
another person's (donor) immune system cells known as aCTL cells, will be safe. This study
will also try to determine if persons who receive aCTL's are more or less likely to survive
their brain tumor than persons who had similar tumors in the past. Approximately 15 patients
will be enrolled at UCLA.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)